Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review.
Che Hsueh YangYen-Chuan OuChi-Chien LinYi Sheng LinMin-Che TungChia-Cheng YuJen-Tai LinChen-Yueh WenPublished in: Life (Basel, Switzerland) (2022)
Currently, medication for benign prostate hyperplasia (BPH) and prostate cancer (PCa) are mainly based on modulating the hormone and nervous systems. However, side effects often affect patients, and might decrease their commitment to continuing the medication and lower their quality of life. Some studies have indicated that chronic inflammation might be the cause of BPH and PCa. Based on this hypothesis, the effect of phloretin, a potent anti-inflammatory and anti-oxidative flavonoid, has been researched since 2010. Results from animal and in-vitro studies, obtained from databases, also indicate that the use of phloretin in treating BPH and PCa is promising. Due to its effect on inflammatory cytokines, apoptosis or anti-apoptosis, reactive oxygen species, anti-oxidant enzymes and oxidative stress, phloretin is worthy of further study in human clinical trials regarding safety and effective dosages.
Keyphrases
- prostate cancer
- oxidative stress
- benign prostatic hyperplasia
- lower urinary tract symptoms
- anti inflammatory
- systematic review
- radical prostatectomy
- clinical trial
- reactive oxygen species
- end stage renal disease
- endoplasmic reticulum stress
- ejection fraction
- dna damage
- newly diagnosed
- endothelial cells
- chronic kidney disease
- induced apoptosis
- cell cycle arrest
- ischemia reperfusion injury
- diabetic rats
- healthcare
- meta analyses
- peritoneal dialysis
- prognostic factors
- emergency department
- patient reported outcomes
- big data
- electronic health record
- heat shock
- pluripotent stem cells